Submit your email to push it up the queue
Bayer Pharmaceuticals Pvt. Ltd., a subsidiary of the global Bayer AG, is headquartered in India and operates extensively across the Asia-Pacific region. Founded in 1863, Bayer has established itself as a leader in the pharmaceutical industry, focusing on innovative healthcare solutions that enhance the quality of life. The company’s core business areas include prescription medications, consumer health products, and specialty pharmaceuticals, with a strong emphasis on therapeutic areas such as cardiology, oncology, and women's health. Bayer's commitment to research and development has led to the introduction of unique products that address unmet medical needs, solidifying its market position as a trusted provider of healthcare solutions. With a rich history of milestones, Bayer Pharmaceuticals continues to make significant contributions to global health, earning recognition for its advancements in medical science and patient care.
How does Bayer Pharmaceuticals Pvt. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bayer Pharmaceuticals Pvt. Ltd.'s score of 81 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bayer Pharmaceuticals Pvt. Ltd., headquartered in India, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Bayer Aktiengesellschaft, which influences its climate commitments and reporting. Bayer Aktiengesellschaft has established various climate initiatives that cascade down to Bayer Pharmaceuticals Pvt. Ltd. These include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the Climate Action 100+ initiative, all of which aim to drive significant reductions in greenhouse gas emissions across their operations. While specific reduction targets for Bayer Pharmaceuticals Pvt. Ltd. are not detailed, the overarching commitments from Bayer Aktiengesellschaft suggest a strong focus on sustainability and climate action. The company is actively engaged in efforts to enhance its environmental performance, aligning with industry standards for climate responsibility. In summary, while Bayer Pharmaceuticals Pvt. Ltd. does not currently provide specific emissions data, it benefits from the climate strategies and targets set by its parent company, Bayer Aktiengesellschaft, reflecting a commitment to reducing carbon emissions and addressing climate change.
Access structured emissions data, company-specific emission factors, and source documents
2008 | 2009 | 2010 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|
Scope 1 | 5,090,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Scope 2 | 3,570,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bayer Pharmaceuticals Pvt. Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.